Insmed, Inc. $INSM Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its stake in Insmed, Inc. (NASDAQ:INSM) by 14.4% during the 4th quarter, Holdings Channel reports. The fund owned 42,388 shares of the biopharmaceutical company’s stock after purchasing an additional 5,337 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Insmed were worth $7,377,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Rakuten Securities Inc. raised its stake in shares of Insmed by 15.3% in the fourth quarter. Rakuten Securities Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $201,000 after acquiring an additional 153 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Insmed by 3.1% in the fourth quarter. Arizona State Retirement System now owns 57,931 shares of the biopharmaceutical company’s stock valued at $10,082,000 after acquiring an additional 1,767 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Insmed by 467.1% in the fourth quarter. Geneos Wealth Management Inc. now owns 414 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 341 shares during the last quarter. HB Wealth Management LLC purchased a new position in Insmed in the fourth quarter valued at $229,000. Finally, KLP Kapitalforvaltning AS increased its holdings in Insmed by 80.5% in the fourth quarter. KLP Kapitalforvaltning AS now owns 74,000 shares of the biopharmaceutical company’s stock valued at $12,879,000 after buying an additional 33,000 shares during the last quarter.

Analysts Set New Price Targets

Several research firms recently commented on INSM. Royal Bank Of Canada increased their target price on Insmed from $212.00 to $216.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Stifel Nicolaus increased their target price on Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Raymond James Financial began coverage on Insmed in a report on Friday, April 10th. They issued an “outperform” rating and a $200.00 target price on the stock. Leerink Partners increased their target price on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. Finally, Barclays increased their target price on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed currently has a consensus rating of “Buy” and a consensus price target of $213.23.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 13,396 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84. Following the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $44,512,131.15. The trade was a 4.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 179,777 shares of company stock valued at $28,252,720. 2.10% of the stock is currently owned by insiders.

Insmed Stock Performance

Shares of INSM stock opened at $143.83 on Friday. The stock’s 50-day moving average is $149.54 and its two-hundred day moving average is $167.10. The firm has a market cap of $31.05 billion, a price-to-earnings ratio of -22.44 and a beta of 1.10. Insmed, Inc. has a 1 year low of $63.81 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) EPS. Analysts predict that Insmed, Inc. will post -2.51 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.